RxDoctor Payments Data

Megan Durkin

Primary Care · Southampton, PANPI 1093494643

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 219 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,878in general payments, 2019–2025

Across 219 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$896
  • Novo Nordisk$433
  • Amgen$421
  • Axsome Therapeutics, Inc.$329
  • AstraZeneca$329
  • Pfizer$223
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,878100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,878 in reported general payments places this provider in the 90th percentile of 300 primary care providers in Pennsylvania.

See all primary care providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$24,642
Metoprolol Succinate27$504
Atorvastatin Calcium27$406
Rosuvastatin Calcium12$316
Amlodipine Besylate11$150
Azithromycin32$118
Prednisone20$41
Meloxicam16$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$223$24,64224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 300 primary care providers in Pennsylvania.

Other primary care in Southampton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →